Survey of Oncology Nurses Reveals Knowledge Gaps Regarding PARP Inhibitor Therapies

Poly(ADP)-ribose polymerase (PARP) inhibition is a new form of targeted therapy that has exhibited effectiveness in treating several solid tumor types. Olaparib (Lynparza®, AstraZeneca), rucaparib (Rubraca®, Clovis Oncology), and niraparib (Zejula®, Tesaro) have all been approved for the treatment of advanced ovarian cancer. Olaparib has also been approved to treat BRCA-mutated breast cancer and is currently being investigated in the treatment of prostate cancer. Another PARP inhibitor, talazopa...
Continue reading

PARP Inhibitor Effective in Advanced Pancreatic Cancer

Poly (ADP-ribose) polymerase (PARP) inhibitors, such as rucaparib (Rubraca®, Clovis Oncology), have been shown to be effective for cancers containing BRCA mutations. They have also been successful as maintenance therapy for platinum-sensitive ovarian cancer treated with PARP inhibitors. Therefore, researchers conducted a phase 2 clinical trial to determine if patients with platinum-sensitive advanced pancreatic cancer and a pathogenic germline or somatic BRCA or PALB2 mutation whose cancer had n...
Continue reading

Copyright © 2020 i3 Health. All rights reserved.